Abstract: A pharmaceutical formulation for topical dental administration or medical (e.g., implant) treatment, including effective amounts of: at least one antimicrobial compound; at least one peroxide source compound; and at least one gel agent. Also disclosed are methods of oral anatomy treatment. The pharmaceutical formulation and treatment methods provide the patient with oral anatomy benefits including, for example, decreased or arrested gum recession; decreased or arrested bone recession; decreased or arrested bone mass loss; decreased or eliminated pain; decreased or eliminated bleeding; decreased or eliminated swelling; enhanced regeneration of bone; enhanced soft tissue repair; or a combination thereof.

Abstract: [Problem] To provide a dental porcelain paste that can maintain a constant paste property even during long-term storage, and that hardly generates carbonization and bubbles during firing even in the case of containing organic components. [Solution] To provide a dental porcelain paste for preparing a dental prosthesis device, comprising (a) base material glass having an average particle diameter D50 of 1 to 20 ?m, (b) hydrophobized fine particle silica having an average primary particle diameter of 1 to 50 nm, (c) organic solvent having a boiling point of 100 to 300° C., and (d) inorganic salt.

Abstract: A concentrated reconstitutable liquid compositions for personal care and a process of making thereof. The composition comprises a blend of sodium lauroyl methyl taurate and sodium lauroyl methyl isethionate in a ratio of 1:2 with solid content of greater than 40%; b. cocamidopropyl betaine with solid content of greater than 40%; c. an antimicrobial preservative; and d. cosmetically and pharmaceutically acceptable auxiliaries. The compositions are low-viscous ‘easy-to-transfer’ and ‘easy-to-hydrate’ and upon dilution with water, afford high viscous ‘ready-to-use’ personal cleansing compositions such as hand-washes, body-washes or shampoos. The liquid compositions of the present invention are based on surfactants only and are free of thickeners such as natural gums or synthetic polymers or other ‘structuring agents’.

Abstract: A dissolvable multilayered capsule, for preparation of cosmetic products, with controllable arrangement of layers, having an impact effect on the dissolvability and/or mixing thereof, based on predetermined interaction between different ingredients incorporated in different layers of the capsule, is described; the method includes: providing a first substance and second substance; determining an impact effect of an interim solution of the first substance, on dissolution and/or mixing of the second substance; defining a desired target effect on dissolution and/or mixing of the multilayered capsule; setting a prioritizing preference for dissolving the first substance before the second substance, based on the impact effect and the desired target effect, and fabricating a multilayered capsule by forming a discreet inner layer and outer layer essentially covering the inner layer, where the first substance is incorporated either within the inner or outer layer discreet layer, based on the prioritizing preference.

Abstract: The present invention is directed to the use of a mineral material as anti-pollution cosmetic agent, wherein the mineral material has a volume median particle size d50(vol) from 0.1 to 90 ?m, a volume top cut particle size d98(vol) of below 250 ?m, and is selected from surface-reacted calcium carbonate, hydromagnesite, or mixtures thereof. Furthermore, the present invention relates to an anti-pollution cosmetic composition comprising said mineral material as well as a cosmetic method of protecting a keratin material from pollutants comprising the application of said anti-pollution cosmetic composition onto the keratin material.

Abstract: This disclosure describes broad-spectrum mineral sunscreen compositions (e.g., in the form of a cosmetic compact or stick), which may be untinted or tinted. Such compositions can comprise effective amounts of (a) two photoprotective metal oxides that detectably or significantly block, reflect, refract, or otherwise attenuate ultraviolet radiation, including (i) at least one zinc oxide particle, possibly an uncoated particle, and having an average particle size of greater than about 100 nanometers (ii) and at least one titanium dioxide particle, possibly a coated particle, (b) an amorphous spherical silica and (ii) material comprising light-altering frustules derived from at least one diatomaceous algal species. In some aspects, the algal material is capable of reflecting or absorbing light in a manner distinct from the zinc/titanium dioxide particles. In some aspects, the compositions are characterizable based on the composition's low water content.

Abstract: The invention is directed to compositions comprising lycopene and to methods of using the same, such as for improving one or more skin parameters. e.g., prevention or treatment of various skin-related conditions caused by ultraviolet radiation.

Abstract: Described herein is a fast-drying perfume composition including at least 70% of one or more fast evaporating solvents and less than 5% of one or more active ingredients. In some embodiments of the invention the solvent is selected from: ethanol, ethyl butyrate, ethyl acetate, isopropanol, 1-propanol, 1-pentanol, aromatic or aliphatic aldehydes with six or fewer C atoms, or fatty alcohols with six or fewer C atoms, 3-methoxy-3-methyl-1-butanol, amyl acetate, 1-pentanol, 2-methyl-1-butanol, 2-pentanol, 3-methyl-2-butanol, isoamyl alcohol, butyl acetate, butyl methyl ether, coconut alkanes, coco-caprylate/caprate, ethyl lactate, ethylene glycol mono n-propyl ether, 1-propanol, propylene glycol monoethyl ether, propylene glycol monomethyl ether acetate, propylene glycol monopropyl ether, lactones with a molecular weight below 80 g/mol, cyclotrisiloxane, cyclotetrasiloxane, cimethicone, octamethyltrisiloxane, and hexamethyldisiloxane.

Abstract: A homeopathic, all-natural formulation to treat skin and wound care has been formulated. It will treat all types of wounds but especially skin care wounds. The formulation is effective in the reduction of biofilm that may promote infection and the formulation is non-toxic and can be applied either in a liquid form or a gel form. The formulation uses a specific combination of all natural ingredients that are combined in a specific ratio to achieve the desired result. The frequency of application of the formula is determined by someone trained in the medical arts in this field.

Abstract: A cosmetic composition comprising (a) one or more higher fatty acids of 12 to 24 carbon atoms or their alkali metal salts, (b) at least one cationic polymer selected from the group consisting of polyquaternium-7 and polyquaternium-22, (c) an anionic surfactant and/or an amphoteric surfactant, and (d) at least one thickener selected from the group consisting of hydrophobized hydroxypropyl methylcellulose, and (meth)acrylic-based polymers comprising a (meth)acryloylalkyltaurine or its salt as a structural unit.

Abstract: It relates to a thickening agent comprising an amidoamine of formula (I)and a N-acylamino acid salt of formula (II), which are as defined in the description. It also relates to sulfate-free personal care cleansing compositions containing the thickening agent.

Abstract: Provided herein are methods for reducing pigmentation, comprising administering to the skin hair, and/or eyes of a subject an effective amount of an nicotinamide nucleotide transhydrogenase (NNT) activator and/or Mitofusin 2 (MFN2) activator, also provided are compositions for use in a method of decreasing pigmentation in the skin, hair, and/or eye of a subject, said method comprising administering the composition to the skin, hair, and/or eye of the subject.

Abstract: Emulsion compositions containing (a) amino acid-based oil agent, (b) lecithin, (c) polyglycerin fatty acid ester, and (d) one or more kinds selected from the group consisting of polyaspartic acid and a salt thereof, and having a pH of 4.5 to 7, are superior in emulsion stability and pH stability and can penetrate between the cells of the stratum corneum layer of the skin.

Abstract: The present disclosure provides compositions of matter comprising a polymer or peptide bound to an oxidized amino acid or an analog thereof. The present disclosure also provides packaging materials, consumer products, and cosmetic products comprising the compositions of matter disclosed herein.

Abstract: The invention relates to a composition comprising at least one oxidation dye coupler chosen from 6-hydroxy benzomorpholine of formula (I), hydroxyethyl-3.4-methy lenedioxyaniline of formula (II). 2-amino-5-ethylphenol of formula (III), one of their addition salts, their solvates and/or the solvates of their salts, and at least one compound chosen from N,N-dicarboxymethyl glutamic acid, one of its salts and mixtures thereof. The invention also relates to a process for dyeing keratin fibres, preferably the hair, comprising the application of the composition to said keratin fibres.

Abstract: A process for reducing hair damage upon exposure to heat is provided, including: providing a cosmetically acceptable aqueous carrier: selecting a heat protectant, wherein the heat protectant is selected based on its ability to impart thermal protection to hair from exposure to heat, wherein the heat protectant is selected to be a functionalized dextran polymer, comprising a dextran polymer functionalized with moieties selected from (i) tertiary amine groups: (ii) quaternary ammonium groups; and (iii) combinations thereof; providing the selected heat protectant; combining the cosmetically acceptable aqueous carrier and the heat protectant to form an aqueous thermal protectant formulation; providing hair; applying the aqueous thermal protectant formulation to the hair to provide protected hair; providing a heat generating hair care appliance; and exposing the protected hair to a temperature of 50 to 300 C using the heat generating hair care appliance for 1 to 30 minutes.

Abstract: Compositions are disclosed herein comprising an ester derivative of a glucan, wherein the glucan has a degree of substitution (DoS) up to about 3.0 with at least one cationic organic group that is ester-linked to the glucan. Methods are further disclosed for preparing these compositions, as well as various applications of using them.

Abstract: Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids.

Abstract: The present invention concerns a composition containing at least one fatty phase and at least one copolymer obtained by polymerization of 0% to 99% by weight, relative to the total weight of the monomers of at least one monomer (A) chosen from 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, isobornyl acrylate, isobornyl methacrylate, and mixtures thereof, 1% to 20% by weight of at least one monomer (B) of formula (I), and 0% to 99% by weight of at least one monomer (C) chosen from C1-C4 alkyl acrylates, C1-C4 alkyl methacrylates, silicone macromonomers and mixtures thereof, relative to the total weight of the monomers,

Abstract: A paste-like silicone composition includes (A) crosslinked organopolysiloxane and (B) oil in a liquid state at 25° C. The component (A) includes a hydrosilylated reaction product of (A-1) organohydrogenpolysiloxane having at least two hydrogen atoms bonded to a silicon atom per molecule, and (A-2) alkenyl group-containing organopolysiloxane having at least two alkenyl groups having 2 to 10 carbon atoms and being bonded to a silicon atom per molecule. Octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane contained in the paste-like silicone composition are each less than 2,000 ppm. It is therefore possible for a stable paste-like silicone composition that has small changes over time such as plasticization return and emit less uncomfortable odor.

Abstract: The present invention pertains to: a novel microorganism; a lysate, a culture, and an extract thereof; and a use thereof for improving hair or scalp condition. A novel Paracoccus denitrificans strain according to an aspect has the effects of promoting hair growth, preventing hair loss, and strengthening hair roots, and can thus be variously applied to improving, preventing, or treating hair or scalp condition. In addition, when the strain is used in combination with one or more Staphylococcus epidermidis strains or yeast extracts, a synergistic effect can be exhibited in improving hair or scalp condition.

Abstract: The invention generally relates to methods and systems for controlling electrolyte excretion, e.g., sodium, potassium, chloride and bicarbonate, which is useful to remove body fluid during sweating.

Abstract: The present invention provides topical pharmaceutical or cosmetic compositions comprising a pharmaceutical or cosmetic carrier comprising at least 3% by weight of phospholipid; at least 20% by weight of C2-C4 alcohol;at least 0.05% by weight keratolytic agent; and optionally, comprising up to 2% by weight of water; and pharmacologically or cosmetically active agent dissolved in said carrier. The compositions are sprayable. Also disclosed is a method of preparing the composition and use thereof, as well as the pharmaceutical or cosmetic carriers as such.

Abstract: The present disclosure relates to transdermal formulations, compositions, and methods for treating or preventing gout or a symptom thereof.

Abstract: Embodiments of the present disclosure provide methods, systems, and apparatuses for aiding weight loss in a patient. According embodiments, an exemplary system for aiding weight loss in a patent comprises a subcutaneous biodegradable medical implant placed or injected in the patient, the biodegradable medical implant comprising naltrexone (C20H23NO4) and capable of releasing the naltrexone from the subcutaneous biodegradable medical implant following the placement of the subcutaneous biodegradable medical implant in the patient; and an optional program comprising behavioral counseling and/or therapy delivered by a licensed professional to the patient.

Abstract: Method and device to treat cancer after surgery in the gastrointestinal tract. The device can be used in a method comprising of removing cancerous cells from a cancerous site on a tissue or organ of a patient, positioning a biodegradable device having a cancer treatment agent to cover the cancerous site, securing the biodegradable device to the cancerous site such that an outer wall of the device extends across the cancerous site, and leaving the biodegradable device at the cancerous site for treatment of microcells left adjacent to the cancerous site.

Abstract: The invention relates to a process for manufacturing oil-in-water emulsions with a PFATs value that remains below 0.05% for at least 24 hours, preferably for at least 48 hours after admixing the emulsions with an amino acid and a glucose solution suitable for parenteral administration.

Abstract: Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are methods for the preparation of the same and their use in formulating and delivering poorly water soluble drugs.

Abstract: The present invention relates an improved process for the preparation of an aqueous ophthalmic solution of difluprednate or pharmaceutically acceptable salts thereof. The present invention further relates to an aqueous ophthalmic solution of difluprednate or pharmaceutically acceptable salts thereof, prepared by the improved process of the present invention.

Abstract: A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.

Abstract: Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega-3 fatty acids (O3FA), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or cicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. Reduction of lung pathology and inflammation will be accomplished by a mixture incorporating O3FA that is suitable for nebulization using formulas and nebulization apparatus known in the art. The O3FA may be delivered in the form of ethyl esters (EE) or free fatty acid (FEA) oils or non-phosphate-containing glycerolipids or as phospholipids (PL) or as any other form known in the art. The mixture can also be delivered in any of the other forms of inhaled droplet or solids for inhalation known in the art. The patient will inhale for a therapeutically effective period of time to reduce inflammation and improve breathing.

Abstract: A polyfunctional radical scavenger hydrogel formulation providing extended protection of the extracellular space within a wound site. The polyfunctional radical scavenger hydrogel formulation is generally formed from a hydrogel, a first radical scavenger and a second radical scavenger differing from the first radical scavenger with respect to at least one property. A portion of the first radical scavenger included with the formation and/or second radical scavenger included within the formulation may be dissolved, suspended and/or bonded to a polymer of the hydrogel.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (1), which is at a pH range of 6 or lower, wherein the buffer (1) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

Abstract: This invention relates to a composition for ophthalmic delivery of a therapeutic agent, the composition comprising an oil-in-water (o/w) microemulsion comprising a fatty acid, or fatty acid ester, as the oil phase; an aqueous phase; a surfactant; and a co-surfactant, and wherein the composition further comprise a suspension of therapeutic agent-loaded nanoparticles. Use of the composition for the treatment or prevention of an eye disorder, a method of treatment or prevention of an eye disorder and an eye drop dispenser are also provided.

Abstract: According to one embodiment, a lipid composition is for delivering an objective substance to a target cell. The composition is contacted with the target cell under an environment of 37° C. or higher. The composition includes a substance delivery carrier having lipid particle and an objective substance encapsulated in the lipid particle. The lipid particle constitutes a liposome and includes FFT-10 and/or FFT-20 as constituents thereof.

Abstract: There is described herein a bilayer nanovesicle comprising porphyrin-phospholipid conjugate and a chelator-fatty acid conjugate; wherein the chelator-fatty acid conjugate comprises an aminopolycarboxylic acid conjugated to a single chain fatty acid; and the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipid.

Abstract: A lipid nanoparticle composition comprising: (i) at least one zwitterionic polymer-containing lipid in which a lipid moiety is covalently attached to a zwitterionic polymer; (ii) at least one non-cationic lipid selected from charged and uncharged lipids, but not attached to a polymer; (iii) at least one cationic or ionizable lipid; and (iv) at least one therapeutic substance, and optionally (v) cholesterol or derivative thereof. Also described herein are methods of delivering a therapeutic substance to a subject, the method comprising administering to the subject a lipid nanoparticle composition described above.

Abstract: The disclosed invention relates to a stable pharmaceutical composition of varenicline or pharmaceutically acceptable salts thereof. More specifically the disclosed invention relates to a pharmaceutical composition comprising varenicline pharmaceutically acceptable salts thereof with daily acceptable limit of nitrosamine impurities.

Abstract: The instant invention relates to a printable material for 3D printing comprising a hydrolyzed and functionalized starch compound. It also relates to a process for 3D printing using the same. It also relates to products, in particular solid dosage forms, obtained thereof by 3D printing.

Abstract: Provided herein are pharmaceutical formulations, methods of manufacturing thereof, and methods of treatment. The pharmaceutical formulations are adapted to serve as a pay load on or in a microbot, and comprise a tablet of a therapeutically effective dose of a pharmaceutical agent and have dimensions such that the tablet may fit on or in the microbot. The pharmaceutical formulation may be formed into, e.g., a cylinder or spheroid of 1 mm dimension, and the pharmaceutical agent may be a small molecule drug, a peptide, a peptoid, a biologic drug, cells, or any combination thereof. Thus, the pharmaceutical formulation of the present description offers delivery of targeted therapy at a locus in a subject, e.g., a tumor.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: By coating an oral solid preparation with a gel film containing a polymer gelable on contact with water, a carbonate, and an acidic substance, obtained oral solid composition is easy to swallow, and elution of active ingredients is suppressed, while the composition can disintegrate in the oral cavity. When an oral solid composition comprising a gel film is hermetically packed or is tightly packed together with a desiccant, discoloration during storage can be suppressed. In a gel film, by setting the concentration of glycerol at 2% by mass or less relative to the total amount of the gel film, mold is prevented from growing. In the case where a coating liquid in which a polymer gelable on contact with water is dispersed is used to form a gel film, the gel film can be formed for a short period of time, even when the coating liquid contains a large amount of the polymer. A gel fil containing titanium oxide at 20% by mass or less can be identifiably marked by ultraviolet laser irradiation.

Abstract: Capsule forming machines that form a dual dosage capsule have superimposed upper and lower plates that are each rotatable about an axis of rotation. Each of the upper and lower plates define a plurality of voids for receiving a shell body or a capsule member of a capsule that are positioned to define a plurality of stations. A first distribution device is operatively positioned at one of the plurality of stations of each of the upper and lower plates and an actuator is operatively connected to either of the upper or lower plates. The actuator moves the upper plate or the lower plate relative to the other plate and/or pivots the upper plate or the lower plate relative to the other plate transverse to the rotational axis to move a capsule assembly station thereof toward to the other plate and then away from the other plate at predetermined times.

Abstract: In one aspect, the disclosure relates to compounds comprising one or more lignin derivatives, at least one organic peroxide, and a pharmaceutically-acceptable carrier. In an aspect, the one or more lignin derivatives can be or include thiolated lignosulfonate (TLS), sodium lignosulfonate (SLS), or a combination thereof. In one aspect, the SLS can be grafted to a polymer or copolymer such as poly(lactic-co-glycolic) acid (PLGA) in order to form a shell of a core-shell nanoparticle, wherein the shell surrounds a core of the inorganic peroxide and protects the core from premature activation in an aqueous wound environment. In another aspect, the pharmaceutically-acceptable carrier can be a hydrogel forming polymer such as a methacrylated gelatin, which can assist in modulating the properties of the lignin derivatives to be suitable for injection. Also disclosed herein are methods of using the disclosed compositions for the treatment of wounds in subjects, including in diabetic subjects.

Abstract: Hypoimmunogenic induced pluripotent stem cell (iPSC)-derived exosomes including tailored chimeric antigen receptor (CARs) which can recognize target biomarkers through an antibody fragment scFV region, bifunctional or ByTE antibodies, by a viral epitope recognition receptor (VERR), VHH nanobody, Variable New Antigen Receptor (VNAR), engineered TCR, or by any single heavy chain IgG fragment from which a variable region can be engineered. A method of making exosomes. A method of treating an individual with cancer, by administering the exosomes to an individual, targeting cancer cells, and treating the cancer. Exosomes including tailored CARs which can recognize target biomarkers through a VERR including viral receptors of an oncolytic virus.

Abstract: Disclosed herein is a composition comprising a lipid nanoparticle and a double-stranded oligodeoxynucleotide (dsODN) encapsulated in the lipid nanoparticle. According to the embodiments of the present disclosure, the dsODN comprises two strands complementary to each other, in which the first strand comprises the nucleotide sequence of SEQ ID NO: 1. Also disclosed herein are methods of treating cancers by using the present composition.

Abstract: Disclosed in the present invention are an ionizable lipid molecule, a preparation method therefor, a composition containing same, an application thereof in the preparation of a vector for delivering a nucleic acid to a cell, and an application thereof in the preparation of a lipid nanoparticle (LNP). By improving the structure of the ionizable lipid molecule and adjusting an LNP component solution, the effect of an mRNA-LNP preparation is improved. The ionizable lipid molecule of the present invention has a structure of formula (I). The ionizable lipid molecule is synthesized with phospholipid, cholesterol, and polyethylene glycol by means of microfluidics to obtain the LNP, and the obtained LNP can improve the translation expression level of a load-mRNA in the cell, improve the effect of the mRNA-LNP preparation, and provide a theoretical basis for theoretical treatment of the personalized mRNA-LNP preparation.

Abstract: A system for stimulating autophagy comprising a sample collection kit (either a buccal swab kit or a lancet kit) and one or more compounds that stimulate autophagy. The buccal swab kit has at least one buccal swab, a collection container, a storage device, a shipping package, a set of instructions, and at least one set of gloves. The lancet kit has at least one sterile lancet or an automated lancet device for capillary bloodletting, a sealed packet with an isopropyl alcohol wipe or pad, a collection container, a storage device, and a shipping package. A method of stimulating autophagy in an individual comprising the steps of providing the individual with at least one sample collection kit, testing the sample provided by the individual to determine the individual's level of autophagy, and administering one or more compounds to the individual to stimulate autophagy on a single use or subscription basis.

Abstract: The present application discloses compositions comprising nanoparticles of vitamin K2, and their methods of use.